Third Party Lab Tests

6/28/2010 Data Showing 100% Safety With LIQUID ZEOLITE™

Do NOT believe the LIES from other companies stating humic/fulvic mineral based liquid zeolite formulations "contain bacteria and fungus".  This is a vicious LIE that still is being perpetuated by those hyping and misrepresenting their greatly overpriced products.  (In fact, one website promoting their greatly overpriced product just shows a "letter of safety" that is over four years old, and not real lab tests of safety).  We have VERY RECENT test data performed by an accredited, independent 3rd party lab for our Liquid Zeolite™ with DHQ (see lab test results above from 6/28/10).  They have "links" on their website, that initially SEEM impressive.  However, looking at what is REALLY presented, there is only ONE link that references a small clinical "test" (hardly a clinical "trial", that is NOT even independent, with less than a dozen subjects; even with Rx drugs, one should view MOST "clinical trials" nowadays very skeptically; click here).  The other "links" quote POWDER zeolite research, not liquid.  The webmaster remembers that up to 14 clinical trials were touted and promised by this website, but only ONE was actually published...  we wonder what "happened" with the OTHER 13 "clinical trials".

Another LIE being perpetuated is that our zeolite is not "cleaned".  We ONLY use ultra cleansed & processed zeolite with our Liquid Zeolite™ with DHQ (click here to see process).  In our cleansing process, the average zeolite cage size is reduced substantially (80% are reduced to sub-micron size which means less than 1 micron, a large percentage being around 1/2 micron in size , while 20% are reduced to 1 to 5 micron size which work wonderful in the intestine).  However, our zeolite is not "nanosized".  Nanosized particles may be dangerous (click here).  Our zeolite does NOT contain "monoatomic gold" or "monoatomic ANYTHING" (click here).  Lastly, we do NOT sell zeolite via "mlm" or "network marketing" (click here).

You should know that our Liquid Zeolite™ is made in a fully GMP compliant lab within the USA.  Good Manufacturing Practices (GMP) Certification Program verifies to consumers that dietary supplements are manufactured according to high standards. The third-party certification program includes inspections of dietary supplement manufacturing facilities to determine whether specified performance standards on a number of measures—including quality control, cleanliness, receiving and testing of raw materials—are being met.  Check other brands of liquid zeolite.  Are they GMP certified?  We are!

Lastly, LIQUID ZEOLITE™ has NO taste, NO smell, and is VERY EASY to take.  Just add to water and drink.

August 2nd, 2010 10:40 PM ET  cnn.com

Permalink Study raises questions about industry funded trials

Drug trials funded by the pharmaceutical industry usually have positive outcomes according to a new study in the Annals of Internal Medicine.

Researchers from the United States and Canada looked at 546 drug trials registered in ClinicalTrials.gov, a registry of both federal and private trials in the United States and abroad. 346 of them, or 63 percen, were funded by the drug industry. The remaining 200 were paid for by government or non-profit organizations. Study authors found that more than 85 percent of industry-funded trials in their sample posted favorable outcomes and were 4 times more likely to report findings that favored their drug.

"We did this study in order to determine whether there is an inherent bias because pharmaceutical companies fund trials on products in which they have a financial interest," said study co-author Dr. Kenneth Mandl of Children's Hospital, Boston. "The most reassuring result would have been that the rate of favorable outcomes would be the same regardless of funding sources. In a very dramatic way that was not the case and what we need to ascertain is if the cause of this shift toward favorable findings among trials funded by pharmaceutical companies is related to the details of the protocols and study design."

Dr. Florence Bourgeois, also of Children's Hospital, Boston and lead author of the study says typically trials sponsored by drug companies are more efficient and well funded. Still, she found the result stunning. "The implications of these findings are that we need more oversight in the way clinical trials are designed as well as in the analysis and reporting of the results. One option may be to make study protocols directly available on clinicatrials.gov as well as the comprehensive reviews complied by the FDA on trial results." She continued, "While we cannot specifically point to which factors contribute to the association between funding source and positive results reporting, our findings speak to the need for more disclosure of all elements of a study."

Most of the trials were Phase 3 or 4, meaning they were large studies to confirm effectiveness and safety. In Phase 4, studies are done after the drug is already on the market but more information is being gathered on things like side effects. Researchers looked at trials for cholesterol medications, antidepressants, blood pressure medication, antipsychotics used for mental disorders like schizophrenia and bipolar disorder and a number of other drugs used to treat other conditions.

According to Mandl, industry funded trials also were less timely in terms of providing public information including trial results. He says even though drug trials are overseen by the Food and Drug Administration, there are still some variables that could favor pharmaceutical companies, including placebo comparisons, dosing and duration. "The concern is the pharmaceutical industry is funding the studies of the drugs in which they have a vested financial interest."

The Pharmaceutical Research and Manufacturers of America (PhRMA) says their member companies are committed to increasing transparency by reporting more information about clinical trials. "The study, published today by the 'Annals of Internal Medicine,' demonstrates one more way that patients and the public health can benefit from increased transparency: The study would not have been possible without the large volume of information about ongoing and completed industry-sponsored clinical trials provided through ClinicalTrials.gov and supported by PhRMA and its member companies."

Dr. Deborah Zarin, Director of ClinicalTrials.gov at the National Institutes of Health says most of the trials used in this study were registered prior to the enactment of the FDA Amendments Act (FDAAA) and therefore were not covered by newer, more stringent registration requirements. "It is clear, however, that some level of selective publication is occurring, so that the public (as well as medical experts) only have access to a biased sample of studies for any given class of drugs. It is therefore urgent that all sponsors of trials, whether government, industry, or others, make strenuous efforts to implement the requirements under FDAAA," she said. "Once this is done, the public will have access to the basic results of key drug and device studies, without being dependent on the interests of the sponsors."